 |
| Contents | |
| The 2000 NIH Consensus Conference on Adjuvant Therapy for Breast Cancer advocated the use of anthracycline-containing regimens, such as cyclophosphamide, doxorubicin, and fluorouracil (CAF) or cyclophosphamide, epirubicin, and fluorouracil (FEC), over non-anthracycline-containing regimens, such as cyclophosphamide, methotrexate, and fluorouracil (CMF) because of a statistically significant survival advantage. However, anthracycline-based therapy can contribute to cardiotoxicity, especially when used in conjunction with trastuzumab. Therefore, the evaluation of taxane-based regimens that might be equivalent or better than anthracycline-based regimens is under way.
Research presented at the 25th Annual San Antonio Breast Cancer Symposium discussed the use of taxane-based therapy in patients with breast cancer, in the neoadjuvant, first-line, and second-line settings. |
| Legal Disclaimer | |
| The materials presented here were prepared by independent authors under the editorial supervision of Medscape, and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or the commercial supporter of the conference, and do not constitute an official part of that conference. The material presented here does not reflect the views of Medical Education Collaborative, Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing medical education activity. Copyright © 2002 Medscape. |
|
|
|
